These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9091723

  • 1. [Acute myelomonocytic leukemia with eosinophilia and inversion of chromosome 16. Study of 6 cases].
    Calvo R, Ribera JM, Millá F, Granada I, Orts M, Batlle M, Flores A, Juncà J, Feliu E.
    Med Clin (Barc); 1997 Feb 08; 108(5):182-5. PubMed ID: 9091723
    [Abstract] [Full Text] [Related]

  • 2. [Long-term results of the UHKT-911 study of adult patients under 65 years of age with de novo acute myeloid leukemias without favorable karyotypes].
    Lemez P, Vítek A, Michalová K, Zemanová Z, Lukásová M.
    Vnitr Lek; 2003 Mar 08; 49(3):174-80. PubMed ID: 12728590
    [Abstract] [Full Text] [Related]

  • 3. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW.
    Bone Marrow Transplant; 1998 Jan 08; 21(2):159-66. PubMed ID: 9489633
    [Abstract] [Full Text] [Related]

  • 4. M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience.
    Pulsoni A, Iacobelli S, Bernardi M, Borgia M, Camera A, Cantore N, Di Raimondo F, Fazi P, Ferrara F, Leoni F, Liso V, Mancini M, Marmont F, Matturro A, Maurillo L, Melillo L, Meloni G, Mirto S, Specchia G, Valentini CG, Venditti A, Leone G, Foà R, Mandelli F, Pagano L.
    Haematologica; 2008 Jul 08; 93(7):1025-32. PubMed ID: 18508801
    [Abstract] [Full Text] [Related]

  • 5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 08; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG, Warkentin PI, Strandjord SE, Abromowitch M, Bayever E, Harper JL, Coccia PF.
    Bone Marrow Transplant; 1997 Jul 08; 20(1):5-10. PubMed ID: 9232249
    [Abstract] [Full Text] [Related]

  • 7. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar 08; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 8. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.
    Haematologica; 1998 May 08; 83(5):422-7. PubMed ID: 9658726
    [Abstract] [Full Text] [Related]

  • 9. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT.
    Szer J, Grigg AP, Phillips GL, Sheridan WP.
    Bone Marrow Transplant; 1993 Feb 08; 11(2):109-11. PubMed ID: 8435660
    [Abstract] [Full Text] [Related]

  • 10. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
    Kröger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G, Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation, German Adjuvant Breast Cancer Study Group, University of California, San Francisco.
    Bone Marrow Transplant; 2003 Dec 08; 32(12):1153-7. PubMed ID: 14647269
    [Abstract] [Full Text] [Related]

  • 11. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M, Lazzarino M, Bernasconi C.
    Haematologica; 1998 Aug 08; 83(8):714-7. PubMed ID: 9793255
    [Abstract] [Full Text] [Related]

  • 12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 08; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 13. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.
    Haematologica; 1998 Jul 08; 83(7):627-35. PubMed ID: 9718868
    [Abstract] [Full Text] [Related]

  • 14. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, Greco G, Buquicchio C, Liso V.
    Ann Hematol; 2003 Apr 08; 82(4):231-5. PubMed ID: 12707726
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.
    Bone Marrow Transplant; 2001 Apr 08; 27(8):829-35. PubMed ID: 11477440
    [Abstract] [Full Text] [Related]

  • 20. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R, Pecci A, Rossi G, Pelizzari AM, Giusto M, Tinelli C, Ascari E.
    Haematologica; 1997 Apr 08; 82(6):660-3. PubMed ID: 9499664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.